Sarepta Therapeutics (SRPT) Phase 1/2 Study of Golodirsen in DMD Hits Statistical Significance on all Primary and Secondary Endpoints
Tweet Send to a Friend
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) today announced muscle biopsy results from its 4053-101 study, a Phase 1/2 first-in-human study conducted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
